PLOS One
Cure8 research brief
Why This Matters
If you have ulcerative colitis, this preclinical study suggests high‑fat diets may worsen intestinal inflammation through metabolic and mitochondrial pathways that impair the gut barrier. Targeting the AMPK/PPARα pathway could be a future therapeutic strategy, especially for patients with metabolic derangements.
Who Should Pay Attention
Researchers studying IBD pathogenesis and metabolic links; clinicians interested in metabolic contributors to UC; patients and advocates curious about diet–inflammation mechanisms.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study used animal and cell models to explore mechanisms: it is not a clinical trial and does not directly test treatments in people.
The main finding is mechanistic — HFD appears to cause lipid accumulation, microbiota changes, oxidative stress, and paradoxical AMPK inactivation that lowers PPARα and fatty‑acid oxidation enzymes, producing mitochondrial injury and impaired barrier integrity. Pharmacologic AMPK activation (AICAR) reversed molecular markers in these models.
The study supports further research into metabolic pathways (AMPK/PPARα) as targets for therapies in UC patients with metabolic dysfunction, but it does not provide evidence that AICAR or other interventions are safe or effective in humans.
Keep In Mind
This is an animal and cell study (mechanistic/basic science) reported in an abstract-format PLOS One article. Findings show molecular effects in models and do not establish clinical benefit or safety in people. AICAR was used experimentally; clinical relevance requires human studies and trials.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPLOS One
PublisherPublic Library of Science (PLoS)
AuthorsHuiyue Pan, Leilei Zhai, Shupeng Zhao +2 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 7, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: the Tianshan Talents Medical and Health Leading Talents Program, award TSYC202401A022
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Poricoic acid a ameliorates ulcerative colitis via AMPK/PPARγ pathway-dependent cellular senescence inhibition and concomitant gut microbiota-metabolome modulation.
This study identifies a plant-derived compound (poricoic acid A) that reduced inflammation, cellular senescence, and colon injury in cell and mouse models of ulcerative colitis and links those effects to AMPK/PPARγ...
Osbeckia opipara attenuates inflammation and reconstructs the intestinal barrier in ulcerative colitis by modulating the AHR/IL-22/STAT3 signaling axis.
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
Single-cell transcriptomic analysis reveals that Trametes robiniophila Murr. (Huaier) granules protect against ulcerative colitis by targeting macrophage-associated cGAS-STING signaling.
The study describes a mechanism by which Huaier granules reduced colitis-related inflammation in mice and cell models by targeting macrophage cGAS–STING signaling and altering the gut microbiome—information that could...